Cancer Research
Page 2 • 9 itemsGain critical insights into global cancer research trends, drug development pipelines, and clinical trial advancements for strategic pharma investment.
Nuvalent to Present Pivotal Neladalkib Data from ALKOVE-1 Trial at ASCO 2026 for ALK-Positive Lung Cancer
Nuvalent will present pivotal ALKOVE-1 trial data for neladalkib in TKI pre-treated ALK-positive NSCLC patients at ASCO 2026, plus zidesamtinib ROS1 data.
Sapience Therapeutics ST316 Shows 47% Response Rate in Phase 2 Colorectal Cancer Trial
ST316, a first-in-class β-catenin antagonist, demonstrated 47% objective response rate and 93% disease control in second-line colorectal cancer patients.
Revolution Medicines Presents Updated Zoldonrasib Phase 1 Data for KRAS G12D Lung Cancer at AACR 2026
Revolution Medicines shares updated Phase 1 clinical trial results for zoldonrasib, targeting KRAS G12D non-small cell lung cancer patients at AACR 2026.
EpiBiologics Begins Phase 1 Trial of EPI-326 Bispecific Antibody for EGFR-Driven Cancers
EpiBiologics doses first patient with EPI-326, a tissue-selective bispecific antibody targeting EGFR-driven solid tumors in global Phase 1 study.
Accent Therapeutics ATX-295 Shows Promising Anti-Cancer Activity in Preclinical Studies at AACR 2026
Accent Therapeutics presents preclinical data for ATX-295, a novel KIF18A inhibitor showing robust anti-cancer activity in chromosomally unstable tumors.
Nuvalent's Zidesamtinib Shows Promise in ROS1-Positive Lung Cancer Patients at AACR 2026
Nuvalent presents positive ARROS-1 trial data for zidesamtinib in ROS1-positive NSCLC patients, showing superior brain penetration vs competitors.
MAIA Biotechnology Activates First U.S. Site for Phase 2 Telomere-Targeting NSCLC Treatment Trial
MAIA Biotechnology launches first U.S. site for international Phase 2 trial of novel telomere-targeting therapy for advanced non-small cell lung cancer.
PDS Biotech's PDS01ADC Shows 78% Response Rate in Metastatic Colorectal Cancer Phase 2 Trial
PDS01ADC demonstrates 78% objective response rate vs 35% control in microsatellite stable metastatic colorectal cancer, offering hope for difficult-to-treat patients.
Actuate Therapeutics' Elraglusib Doubles Pancreatic Cancer Survival Rates in Nature Medicine Study
Elraglusib plus chemotherapy doubled 1-year survival rates to 44% vs 22% in metastatic pancreatic cancer patients, published in Nature Medicine.